Departments
Professor Yolande Pijnenburg delivers her inaugural lecture on 'Young-onset dementia’ today. She emphasizes the difference in symptoms of dementia in younger patients, which results in late recognition of this condition.
For severe developmental disabilities, we must dare to break with simplifications such as autism and ADHD, and reverse the perspective. Hilgo Bruining will deliver his inaugural lecture on May 18, 2022, at the University of Amsterdam.
Researchers from Amsterdam UMC, as part of the Growing Up Together in Society (GUTS) consortium, receive 22 million euros to discover how young people can grow up successfully and contribute to the current and future society.
Vrije Universiteit Amsterdam and Amsterdam UMC have received the Gravitation Grant for the development of new methods to measure stress in daily life as well as to reduce it and thereby prevent the development of stress-related diseases.
Anxiety disorders and chronic insomnia are the two most common psychiatric conditions. A team of sleep researchers, led by professor Eus van Someren will now study these two disorders in combination.
In the largest genetic study ever of schizophrenia, researchers mapped the genes of more than 300,000 people with and without schizophrenia. A significant proportion of the genetic variants they found appear to be involved in signal transmission between nerve cells.
The Alzheimer's Drug Discovery Foundation is investing in the development of a multi-analytical plasma test for early detection of Alzheimer's disease. Charlotte Teunissen, professor of Amsterdam Neuroscience, will lead the prospective clinical studies to validate the test.
Translational Neuroscience Network stands for connecting fundamental and clinical researchers in the field of translational neuroscience. During the 2021 Fall and 2022 Spring Amsterdam Neuroscience organizes a series of TN2 webinars: the research program edition.
Amsterdam Neuroscience professor Eric Reits has been awarded a NWA-ORC grant. Together with 15 partners, Reits will use the 5.5 million euros funding to predict, delay, and cure polyglutamine-caused neurodegeneration.
